At 3 months, findings showed 80.4% of patients treated with Juvéderm Voluma XC achieved at least a 1-point improvement in moderate to severe temple hollowing. The Food and Drug Administration (FDA) ...

IRVINE, Calif., Sept. 23, 2025 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today announced the roll-out of SKINVIVE by JUVÉDERM® in 35 additional markets this year bringing ...